Is postoperative radioactive iodine associated with a survival advantage among…
References
- American Cancer Society. ‘Cancer facts, figures2013.http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-036845.pdf Accessed’ November 30, 2014.
- DeSantis CE, Lin CC, Mariotto AB, et al. ‘Cancer treatment and survivorship statistics’, 2014. CA Cancer J Clin. 2014;64:252–271.
- Haugen BR, Alexander EK, Bible KC et al. ‘American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.’ Thyroid. 2016; 26(1):1–133.2646296710.1089/thy.2015.0020
- Davies L, Welch HG. ‘Thyroid cancer survival in the United States: observational data from 1973 to 2005’. Arch Otolaryngology Head Neck Surg. 2010;136:440–444.10.1001/archoto.2010.55
- Jonklaas J, Sarlis NJ, Litofsky D, et al. ‘Outcomes of patients with differentiated thyroid carcinoma following initial therapy’. Thyroid. 2006;16:1229– 1242.10.1089/thy.2006.16.1229
- Morris LF, Romero Arenas MA, et al. ‘Streamlining variability in hospital charges for standard thyroidectomy: developing a strategy to decrease waste.’ Surgery. 2014;156:1441–1449.10.1016/j.surg.2014.08.06825456929
- Castagna, M. G., S. Cantara, and F. Pacini. ‘Reappraisal of the indication for radioiodine thyroid ablation in differentiated thyroid cancer patients: Journal of Endocrinological Investigation.’ 2016; 39:1087–1094.
- Mendoza A, Shaffer B, Karakla D, et al. ‘Quality of life with well-differentiated thyroid cancer: treatment toxicities and their reduction.’ Thyroid. 2004;14:133–140.[PubMed]10.1089/10507250432288037315068628
- Almeida JP, Sanabria AE, Lima EN, et al.. ‘Late side effects of radioactive iodine on salivary gland function in patients with thyroid cancer.’ Head Neck. 2011;33:686–690.[PubMed]2148491710.1002/hed.21520
- Sawka AM, Thabane L, Parlea L, et al. ‘Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis.’ Thyroid. 2009;19:451–457. [PubMed]10.1089/thy.2008.039219281429
- Iyer NG, Morris LG, Tuttle RM, et al. ‘Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy.’ Cancer. 2011;117:4439–4446.[PMC free article][PubMed]2143284310.1002/cncr.26070
- Podnos YD, Smith DD, Wagman LD, et al. ‘Survival in patients with papillary thyroid cancer is not affected by the use of radioactive isotope’ .J Surg Oncol. 2007;96:3–7.[PubMed]10.1002/jso.20656
- Jonklaas J, Sarlis NJ, Litofsky D, et al. ‘Outcomes of patients with differentiated thyroid carcinoma following initial therapy.’ Thyroid. 2006;16:1229– 1242.[PubMed]1719943310.1089/thy.2006.16.1229
- Hay ID, Thompson GB, Grant CS, et al. ‘Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940–1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients.’ .World J Surg. 2002;26:879–885.[PubMed]10.1007/s00268-002-6612-1
- Ewa Ruel, Samantha Thomas, Michaela Dinan, et al. ‘Adjuvant Radioactive Iodine Therapy Is Associated With Improved Survival for Patients With Intermediate-Risk Papillary Thyroid Cancer.’ J ClinEndocrinolMetab. 2015 Apr; 100(4): 1529– 1536.
- M. G. Castagna1, S. Cantara, F. Pacini. ‘Reappraisal of the indication for radioiodine thyroid ablation in differentiated thyroid cancer patients.’ J Endocrinol Invest (2016) 39:1087–10942735055610.1007/s40618-016-0503-z
- Adam MA, Pura J, Goffredo P et al . ‘Presence and number of lymph node metastases are associated with compromised survival for patients younger than age 45 years with papillary thyroid cancer.’ J ClinOncol. 2015;33:2370–237510.1200/JCO.2014.59.8391
- Randolph GW, Duh QY, Heller KS et al. ‘The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension.’ Thyroid.2012 22:1144–115210.1089/thy.2012.004323083442
Language: English
Page range: 23 - 27
Submitted on: Apr 11, 2017
Accepted on: Aug 24, 2017
Published on: Jun 30, 2017
Published by: Helenic Society of Medical Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 2 times per year
Related subjects:
© 2017 Rasha Hamdy Hamed, published by Helenic Society of Medical Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.